AELIS FARMA

𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗮𝘆 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝗗𝗿𝘂𝗴 𝗔𝗯𝘂𝘀𝗲 𝗮𝗻𝗱 𝗜𝗹𝗹𝗶𝗰𝗶𝘁 𝗧𝗿𝗮𝗳𝗳𝗶𝗰𝗸𝗶𝗻𝗴 By resolution 42/112 of 7 December 1987, the General Assembly of the United Nations decided to observe 26 June as the International Day against Drug Abuse and Illicit Trafficking as an expression of its determination to strengthen action and cooperation in achieving a world free of drug abuse. 𝗧𝗵𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗶𝘀 𝗰𝗹𝗲𝗮𝗿: 𝗶𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 At Aelis Farma, we believe that preventing addiction should include the early detection of drug use disorders to enhance treatment efficacy. Unfortunately, most individuals seek treatment for drug use disorders only when their condition has become severe, making treatment more challenging. Detecting mild drug use disorders and offering treatment at this early stage could be transformative in preventing the progression to addiction. At Aelis Farma, we are dedicated to developing impactful treatment solutions that can make a real difference in people's lives. Currently, we are fully committed to advancing our first drug candidate, AEF0117, for the treatment of cannabis use disorders (CUD). Stay tuned for the results of the phase 2b study of AEF0117 in CUD in Q3 2024. Let's use this day as an opportunity to come together, educate ourselves and others, and support those who may be struggling. Together, we can build healthier, happier communities. #WorldDrugDay #InvestInPrevention #AELIS #cannabis #CUD #addiction #SAMHSA #neurosciences #cognition #CB1

𝗣𝗶𝗲𝗿 𝗩𝗶𝗻𝗰𝗲𝗻𝘇𝗼 𝗣𝗶𝗮𝘇𝘇𝗮, 𝗖𝗘𝗢 𝗼𝗳 𝗔𝗲𝗹𝗶𝘀 𝗙𝗮𝗿𝗺𝗮, 𝗶𝗻 𝘁𝗵𝗲 𝗺𝗲𝗱𝗶𝗮! 👨⚕️ 🔬 Pier Vincenzo Piazza, CEO of Aelis Farma, interviewed exclusively by L'Express. This insightful conversation covers Aelis Farma's innovative approach to treat cannabis addiction, groundbreaking developments of the new pharmaceutical class of CB1-SSi and Pier Vincenzo Piazza's vision for the future of addiction. Don't miss out on this opportunity to learn more on cannabis addiction. Link to the article in comment 👇 #AELIS #biotech #cannabis #CUD #SAMHSA #neurosciences #cognition

AELIS FARMA’s AEF0117 pour l’addiction au cannabis Merci à BFMTV pour ce reportage

Aelis Farma Daycare Initiative has launched !!!! We are happy to contribute to more inclusive scientific conferences

📢 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀!  We are thrilled to announce that Pier Vincenzo Piazza, CEO of Aelis Farma, will be presenting our groundbreaking research with AEF0217 in Down syndrome at the 5𝑡ℎ 𝑇21 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑆𝑜𝑐𝑖𝑒𝑡𝑦 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑐𝑜𝑛𝑓𝑒𝑟𝑒𝑛𝑐𝑒 in Rome. Join us as we delve into innovative therapies and discuss the future of treatment for individuals with Down syndrome. This is a fantastic opportunity to connect with leading experts and advance our shared mission of improving lives by rescuing cognitive performances. 📅 Date: 5-8 June 2024  📍 Location: Rome, Italy We look forward to seeing you there! #AELIS #biotech #T21RS #Downsyndrome #neurosciences #cognition #trisomie21 #ICOD

𝗪𝗲 𝗮𝗿𝗲 𝗱𝗲𝗹𝗶𝗴𝗵𝘁𝗲𝗱 𝘁𝗼 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲 𝘁𝗵𝗮𝘁 𝗼𝘂𝗿 𝗖𝗘𝗢 𝗣𝗶𝗲𝗿 𝗩𝗶𝗻𝗰𝗲𝗻𝘇𝗼 𝗣𝗶𝗮𝘇𝘇𝗮 𝘄𝗶𝗹𝗹 𝗴𝗶𝘃𝗲 𝗮 𝗽𝗹𝗲𝗻𝗮𝗿𝘆 𝗹𝗲𝗰𝘁𝘂𝗿𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗗𝗮𝘆 𝗼𝗻 𝗔𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻𝘀. 📢 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗡𝗲𝘄𝘀!   The National Translational Research Day on Addictions, is organized under the auspices of REUNIRA (National Network for Alcohol Research). Pier Vincenzo Piazza (CEO of Aelis Farma) lecture "A New Treatment for Cannabis Addiction: From Animal Models to Patients." will focus on the history of the development of the new pharmacological class developed by Aelis Farma the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi) and of its first drug candidate AEF0117. This event is open to all and will take place at the French Ministry of Solidarity and Health (Paris 7). Registration link in the comments. 📅 June 3, 2024 🕙14h30 📍 Ministère des Solidarités et de la Santé | Paris 07 #AELIS #biotech #Reunira #cannabis #CUD #SAMHSA #neurosciences #cognition #cannabinoids #CB1 #THC #addiction #psychiatry

𝐌𝐞𝐞𝐭 𝐮𝐬 𝐚𝐭 𝐁𝐈𝐎 𝟐𝟎𝟐𝟒 𝐢𝐧 𝐒𝐚𝐧 𝐃𝐢𝐞𝐠𝐨, 𝐉𝐮𝐧𝐞 𝟑-𝟔, 𝟐𝟎𝟐𝟒 ⌚ Come and join us to the most important partnering event in the US. Book a meeting and connect with Stéphanie Monlezun, Chief Operating Officer and Arsene Guekam, Chief Corporate Development Officer, to gain insights into our innovative pipeline and on partnership opportunities! Looking forward to seeing you at #BIO2024! #BIO2024 #BD #Partnering  #Biotech  #CognitiveDeficits #Downsyndrome  #CB1receptor #Neurosciences

Celebrating The National Prevention Week This week marks the National Prevention Week, an initiative led by SAMHSA (Substance Abuse and Mental Health Services Administration) to raise awareness about mental health and substance abuse issues. At Aelis Farma, we stand in solidarity with this crucial cause. We believe that prevention of addiction should include early detection of drug use disorders to facilitate treatment efficacy. You do not wait for cancer to be metastatic before treating it, we all well know that success is linked to early detection. Unfortunately, most people seek treatment for drug use disorders when their condition is severe and treatment more difficult. Detecting mild drug use disorders and proposing treatment at this early stage could be a game changer in preventing the development of addiction. At Aelis Farma, we strive to develop impactful treatment solutions to make a difference in people's lives and are currently fully committed to develop our first drug candidate AEF0117 for the treatment of cannabis use disorders (CUD). Stay tuned for the results of the phase 2b study of AEF0117 in CUD in Q3 2024 . Let's use this week as an opportunity to come together, educate ourselves and others, and support those who may be struggling. Together, we can build healthier, happier communities. #NationalPreventionWeek #AELIS #cannabis #CUD #SAMHSA #neuroscience #cognition #cannabinoids #CB1 #THC #addiction

𝗣𝗨𝗕𝗟𝗜𝗖𝗔𝗧𝗜𝗢𝗡 𝗢𝗙 𝗢𝗨𝗥 𝟮𝟬𝟮𝟯 𝗨𝗡𝗜𝗩𝗘𝗥𝗦𝗔𝗟 𝗥𝗘𝗚𝗜𝗦𝗧𝗥𝗔𝗧𝗜𝗢𝗡 𝗗𝗢𝗖𝗨𝗠𝗘𝗡𝗧 Showing our continued commitment to transparency and excellence in corporate governance, the Universal Registration Document (URD) provides comprehensive insights into Aelis Farma’s operations, financial performance, governance, and strategic outlook. The URD includes the Annual Financial Report, the statutory auditor’s reports, information relating to corporate social responsibility and more. Beyond fact and figures, the Universal Registration Document also presents a deep insight into our science, development strategy, vision and future milestones. Explore our URD and learn more about Aelis’s mission and aspirations. We are confident to achieve our goals and progress towards becoming a leading player in the field of brain disease. 👉 The URD can be downloaded via the link provided in the comment or on the Company’s website under the Investors / Documentation section.   #AELIS #biotech #downsyndrome #cannabisaddiction #neuroscience #cognitiveimpairements #cognition #cannabis #CB1 #cannabinoids #addiction #neurodevelopment

𝗖𝗢𝗠𝗣𝗟𝗘𝗧𝗜𝗢𝗡 𝗢𝗙 𝗧𝗛𝗘 𝗟𝗔𝗦𝗧 𝗩𝗜𝗦𝗜𝗧 𝗢𝗙 𝗧𝗛𝗘 𝗟𝗔𝗦𝗧 𝗣𝗔𝗧𝗜𝗘𝗡𝗧 𝗜𝗡𝗖𝗟𝗨𝗗𝗘𝗗 𝗙𝗢𝗥 𝗧𝗛𝗘 𝗣𝗛𝗔𝗦𝗘 𝟮𝗯 𝗧𝗥𝗜𝗔𝗟 𝗪𝗜𝗧𝗛 𝗔𝗘𝗙𝟬𝟭𝟭𝟳 𝗙𝗢𝗥 𝗧𝗛𝗘 𝗧𝗥𝗘𝗔𝗧𝗠𝗘𝗡𝗧 𝗢𝗙 𝗖𝗔𝗡𝗡𝗔𝗕𝗜𝗦 𝗔𝗗𝗗𝗜𝗖𝗧𝗜𝗢𝗡 🔔 Aelis Farma is pleased to announce this important milestone for the development of AEF117 which proves once again our ability to respect timelines.  👉 This phase 2b with AEF0117 has included 333 patients, becoming the largest study ever conducted for the treatment of cannabis addiction, an increasingly serious medical concern 👉 This major milestone paves the way for the release of study results on Q3 aimed to demonstrate that AEF0117 is the first efficacious treatment of cannabis addiction 👉 Indivior retains a $100 million license option, exercisable within 90 days of positive phase 2b results and FDA feedback at future End of Phase 2 (EOP2) meeting Congratulations to the extremely dedicated Aelis team! 💪 #AELIS #biotech #cannabisaddiction #CUD #cognition #psychiatry #neuroscience